Clinical Trials on Bronchial Neoplasms in China

Total 18565 results

The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Allist Pharmaceuticals, Inc.

Unknown

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Advanced NSCLC

China
Zhujiang Hospital
Sun Yat-sen University; Nanfang Hospital of Southern Medical University; The...

Unknown

Molecular Profiling in Small Cell Lung Cancer (MPSCLC)

Lung Neoplasms | Small Cell Lung Cancer

China
Third Military Medical University

Unknown

SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC

Small Cell Lung Cancer

China
Third Military Medical University

Unknown

Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer (TDICC)

Small Cell Lung Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China
Tongji University

Unknown

The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer

Small Cell Lung Cancer

China
Caicun Zhou

Unknown

Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

China
Eli Lilly and Company

Completed

Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer

Non-Small Cell Lung Cancer

China
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Guangzhou Medical University

Unknown

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Small Cell Lung Cancer | Metastatic Carcinoma

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer (OWBLM)

Non-small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

NSCLC | Solid Tumor

China
Qilu Hospital of Shandong University

Unknown

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Advanced Nsclc

China
Three Gorges Hospital of Chongqing University

Recruiting

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Non-small Cell Lung Cancer

China
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Hunan Province Tumor Hospital

Completed

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Non-squamous NSCLC

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC (SHARP)

Small-cell Lung Cancer | Brain Metastases | SRS | Stereotactic Radiotherapy | Whole Brain Radiotherpay | Hippocampal-avoidance

China
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Brain Metastases | Stage IV Non-small Cell Lung Cancer

China
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

NSCLC | Neoadjuvant Therapy

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Shanghai Chest Hospital

Recruiting

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Non Small Cell Lung Cancer

China
InventisBio Co., Ltd

Completed

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NSCLC | Solid Tumor | EGFR T790M

China
AnHeart Therapeutics Inc.

Active, not recruiting

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Non Small Cell Lung Cancer

China
Fudan University

Completed

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Non-small-cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Trial in Chinese Healthy Volunteers of GB222

Non-small Cell Lung Cancer

China
Chinese PLA General Hospital

Unknown

Liquid Biopsy for Detection of Driver Mutation in NSCLC

Non Small Cell Lung Cancer

China
Baohui Han

Completed

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. (ML25444)

Non Small Cell Lung Cancer

China
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Shandong Cancer Hospital and Institute
Qilu Hospital of Shandong University; Shandong Provincial Hospital; The Affiliated...

Unknown

Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases (SMART-Brain)

Brain Metastases

China
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Shandong Cancer Hospital and Institute

Unknown

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients (CRAGMOLC)

Carcinoma, Non-Small-Cell Lung

China
Lunxu Liu

Terminated

Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients

NSCLC

China
First Affiliated Hospital, Sun Yat-Sen University

Unknown

The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation

Carcinoma, Non-Small-Cell Lung

China
Ruijin Hospital
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression (TOPLINE)

Carcinoma, Non-Small-Cell Lung

China
Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
The First Affiliated Hospital with Nanjing Medical...
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Unknown

Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC (CSOAIMTOAN)

Nonsmall Cell Lung Cancer

China
The First People's Hospital of Lianyungang
Hengrui Yuanzheng Bio-Technology Co., Ltd.

Unknown

Neo-MASCT Immunotherapy for Advanced NSCLC.

NSCLC Stage IV

China
Sun Yat-sen University

Recruiting

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Non-small Cell Lung Cancer

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Shanghai Henlius Biotech

Recruiting

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer

China
Fudan University
Allist Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Non-Small-Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (SACHI)

Non-small Cell Lung Cancer

China

3

Subscribe